Novartis AG (NYSE:NVS) will release its earnings data before the market opens on Tuesday, October 24th. Analysts expect Novartis AG to post earnings of $1.25 per share for the quarter.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The firm had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same period in the previous year, the business posted $1.23 earnings per share. The company’s revenue for the quarter was down 1.8% compared to the same quarter last year. On average, analysts expect Novartis AG to post $4.76 EPS for the current fiscal year and $5.09 EPS for the next fiscal year.

Novartis AG (NYSE:NVS) opened at 86.37 on Tuesday. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The company has a market capitalization of $202.36 billion, a PE ratio of 31.53 and a beta of 0.73. The firm’s 50-day moving average is $85.27 and its 200-day moving average is $81.90.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/17/novartis-ag-nvs-set-to-announce-earnings-on-tuesday.html.

A number of research analysts have issued reports on the company. BidaskClub downgraded Novartis AG from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Cowen and Company set a $90.00 price objective on Novartis AG and gave the company a “hold” rating in a research note on Wednesday, August 9th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, October 10th. Finally, Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $84.13.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Earnings History for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.